Vidofludimus

Base Information

Chemical Name:Vidofludimus
CAS No.:717824-30-1
Molecular Formula:C20H18FNO4
Molecular Weight:355.366
Hs Code.:
European Community (EC) Number:615-418-4
UNII:8Y1PJ3VG81
DSSTox Substance ID:DTXSID50431325
Wikidata:Q27271184
NCI Thesaurus Code:C152873
Pharos Ligand ID:J34FTRYTYGPL
Metabolomics Workbench ID:155498
ChEMBL ID:CHEMBL197194
Mol file:717824-30-1.mol

Synonyms:2-(3-fluoro-3'-methoxybiphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid;4SC-101;vidofludimus

Suppliers and Price of Vidofludimus

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

TRC
Vidofludimus
25mg
$ 330.00

DC Chemicals
Vidofludimus(4SC-101;SC12267) >98%
100 mg
$ 300.00

DC Chemicals
Vidofludimus(4SC-101;SC12267) >98%
250 mg
$ 600.00

Crysdot
Vidofludimus 98+%
50mg
$ 812.00

Crysdot
Vidofludimus 98+%
25mg
$ 427.00

ChemScene
Vidofludimus 98.75%
5mg
$ 90.00

ChemScene
Vidofludimus 98.75%
10mg
$ 150.00

ChemScene
Vidofludimus 98.75%
50mg
$ 450.00

ChemScene
Vidofludimus 98.75%
100mg
$ 640.00

Chemenu
2-((3-fluoro-3''-methoxy-[1,1''-biphenyl]-4-yl)carbamoyl)cyclopent-1-ene-1-carboxylicacid 98%
100mg
$ 818.00

Total 25 raw suppliers

Chemical Property of Vidofludimus

Chemical Property:

Boiling Point:567.5±50.0 °C(Predicted)
PKA:4?+-.0.20(Predicted)
PSA：79.12000
Density:1.354±0.06 g/cm3(Predicted)
LogP:4.65440
Solubility.:insoluble in H2O; insoluble in EtOH; ≥103 mg/mL in DMSO
XLogP3:3.4
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:5
Exact Mass:355.12198622
Heavy Atom Count:26
Complexity:576

Purity/Quality:

99%, ^*data from raw suppliers

Vidofludimus ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
Recent ClinicalTrials:Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
Recent EU Clinical Trials:A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Uses Vidofludimus is an immunosuppressive drug that inhibits dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma.

Technology Process of Vidofludimus

There total 2 articles about Vidofludimus which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: